A new monoclonal antibody that targets HER2+ in breast cancer, margetuximab-cmkb (Margenza), has been popular by the Meals and Drug Administration (FDA). The brand new…
A new monoclonal antibody that targets HER2+ in breast cancer, margetuximab-cmkb (Margenza), has been popular by the Meals and Drug Administration (FDA). The brand new…